GT-1 (LCB10-0200) is a siderophore-linked cephalosporin compound that effectively combats clinical isolates of various bacterial species, including P. aeruginosa, Klebsiella oxytoca, Proteus spp., Serratia marcescens, and Enterobacter aerogenes.

Fulvotomentoside B, a saponin derived from Lactobacillus flavus, displays hepatoprotective properties. It notably decreases serum glutamate pyruvate transaminase (SGPT) and triacylglycerol (GT) concentrations in mice subjected to hepatic injury induced by CCl₄, d-galactosamine (d-gal), and acetaminophen, while also significantly mitigating liver tissue damage [1].

L-796568, is a β3 adrenergic receptor agonist. L-796568 is a potent full beta(3) agonist (EC(50) = 3.6 nM, 94% activation) with >600-fold selectivity over the human beta(1) and beta(2) receptors, which also displays good oral bioavailability in several

NS5A-IN-2 (Compound 33) serves as a potent NS5A inhibitor exhibiting exceptional efficacy against HCV genotype 1b, enhanced activity against genotype 3a (GT 3a), and notable metabolic stability [1].

NS5A-IN-3 (Compound 15) serves as a potent NS5A inhibitor, displaying exceptionally high efficacy against HCV genotype 1b, enhanced activity towards genotype 3a (GT 3a), and substantial metabolic stability. It also demonstrates a superior resistance barrier compared to daclatasvir in genotype 1b [1].